After the earlier treatment has finished, participants are assigned to receive either pumitamig or durvalumab. The study is randomized, which means the treatment is chosen by chance, and open-label, which means the treatment is known. The study team then follows the cancer over time and watches for changes, such as whether it stays stable, shrinks, or grows, and also checks how safe each medicine is and how well it is tolerated.

The study will test a medication called cemiplimab (also known as LIBTAYO), which is given through an intravenous infusion. This medicine belongs to a group of drugs called immunotherapy, which helps the body’s immune system fight cancer cells. The purpose is to determine if giving cemiplimab after surgery can help prevent the cancer from returning, compared to patients who receive no additional treatment after surgery.

During the study, participants will either receive cemiplimab treatment or be observed without treatment. The medication will be given through an infusion into a vein every few weeks. The total treatment period may last up to 42 weeks. Doctors will monitor the participants’ health and check if the cancer returns during and after the treatment period.

The purpose of this research is to determine if using THIO followed by cemiplimab helps patients with advanced NSCLC live longer compared to using standard chemotherapy alone. Both treatments are given through an intravenous infusion, which means the medication is delivered directly into the bloodstream through a vein.

During the study, patients will be randomly assigned to receive either the THIO/cemiplimab combination or one of the standard chemotherapy medications. The treatment period may continue for up to 24 months. Throughout the study, doctors will monitor patients’ health and track how their cancer responds to the treatment. They will also watch for any side effects that may occur during the treatment period.

The purpose of this study is to determine how effective the combination of these medications is at eliminating cancer cells before surgery. The treatment is given in two phases – before surgery (called neoadjuvant treatment) and after surgery (called adjuvant treatment). Before surgery, patients receive both medications. After surgery, all patients receive zimberelimab, and some patients may also continue receiving sacituzumab govitecan.

During the study, patients will receive regular medical examinations and various tests to monitor their health and how well the treatment is working. The treatment period may last up to 54 weeks. Zimberelimab is given at doses up to 360 milligrams, while sacituzumab govitecan is given based on the patient’s body weight, up to 10 milligrams per kilogram of body weight.

The study is divided into two parts to determine the best way to use these medicines. In the first part, different amounts of the drugs are given to find the safest and most effective dose. The second part focuses on finding the optimal dose and observing how well the combination works for different types of lung cancer. Throughout the process, the safety and how the body processes the drugs are closely monitored.

The study is divided into different parts. The first part will test different dose levels of the investigational medications to find the most suitable dose for further testing. During this phase, doctors will carefully monitor participants for any side effects. The following parts of the study will test the chosen dose in larger groups of people with advanced non-small cell lung cancer to better understand how well the treatment works and how safe it is. Throughout the study, participants will receive the medications through infusion into a vein. Doctors will regularly check how the cancer responds to treatment using imaging scans and other assessments.

During the study, participants will need to provide a tissue sample from their tumor, either from a previously stored sample or from a new biopsy if needed. The study will track various aspects of participant health and treatment response, including any side effects that occur, whether the cancer shrinks or stops growing, and how long any positive effects last. Blood samples will be collected at different times to measure the levels of the investigational medications in the body and to check whether the immune system develops a response to these medications.

The main purpose of this research is to test how safe and effective this combination treatment is for patients whose cancer has returned after previous therapy. The study will monitor how well patients tolerate the treatment and how it affects the progression of their disease. Some patients in the study may also have up to three areas where the cancer has spread to other parts of the body.

During the study, participants will receive radiotherapy treatment first, followed by both medications. Durvalumab will be given as an infusion at a dose of up to 1500 mg, while ceralasertib will be taken as tablets with a maximum daily dose of 480 mg. The treatment period may continue for up to 36 months, during which patients will have regular check-ups to monitor their health and how well the treatment is working.

The purpose of the study is to evaluate the safety and effectiveness of BNT327 when used with chemotherapy. The trial is divided into two phases: Phase II and Phase III. In Phase II, the focus is on assessing how safe and tolerable BNT327 is at different dose levels when combined with chemotherapy. In Phase III, the study will compare the effectiveness of BNT327 combined with chemotherapy to the combination of pembrolizumab and chemotherapy. The study will also look at how these treatments affect the progression of the disease and overall survival of participants.

Participants in the study will receive treatment over a period of time, with regular follow-up visits to monitor their health and the effects of the treatment. The study aims to provide valuable information on the potential benefits and risks of using BNT327 in treating non-small cell lung cancer, which could lead to new treatment options for patients in the future.

The purpose of the study is to evaluate how well this combination of treatments works in preparing patients for surgery. The study will look at how many patients can have a complete removal of their tumor through surgery after receiving the treatment. Participants will receive the treatment over a period of time before undergoing surgery. The study will also monitor other outcomes, such as the reduction of cancer in the lymph nodes, the response of the tumor to the treatment, and the overall survival of the patients.

Throughout the study, participants will receive regular assessments to monitor their health and the progress of the treatment. The study aims to provide valuable information on the effectiveness of combining tislelizumab with chemotherapy in treating this specific type of lung cancer, potentially leading to improved treatment options for patients in the future.

The purpose of this study is to determine how well this combination of treatments works in patients with this type of lung cancer. Participants will receive these medications in a specific order, starting with the combination of chemotherapy and immunotherapy, followed by a type of radiation therapy called hypofractionated radiotherapy. This means the radiation is given in larger doses over a shorter period of time. The study will monitor how the cancer responds to the treatment and how long patients remain free from cancer progression.

Throughout the study, participants will be closely monitored for any side effects and changes in their health. The study will also assess the overall quality of life of the participants during and after the treatment. The goal is to find out if this treatment approach can improve the outcomes for patients with this challenging type of lung cancer.

The study is divided into two groups, or cohorts. In the first group, researchers are looking at patients who continue to receive durvalumab along with a single chemotherapy drug to see if this combination helps them live longer. In the second group, the study is examining whether continuing durvalumab after initial treatments can improve survival in patients whose cancer has returned. The trial will follow participants over a period of time to monitor their health and any changes in their condition.

Throughout the study, researchers will collect information on how long patients live, how long they remain free from cancer progression, and how their bodies respond to the treatment. They will also monitor the safety of the treatment and any side effects that may occur. This information will help determine the effectiveness of durvalumab in treating relapsed NSCLC and provide insights into potential future treatments for this type of lung cancer.

The purpose of this research is to determine how effective a combined treatment approach is for patients with this type of lung cancer. The treatment plan includes initial therapy with immunotherapy and chemotherapy, followed by either surgery or a combination of chemotherapy and radiation therapy. After these treatments, patients receive additional immunotherapy for up to 12 months.

During the study, patients will receive medications through infusion, which means the drugs are given directly into a vein. Doctors will monitor how well the treatment works and track any side effects that may occur. The study will measure how long patients live without their cancer getting worse or returning after treatment begins.

Participants in the study will receive Alectinib as a single treatment, meaning no other cancer treatments will be given alongside it. The study will observe how the cancer responds to the medication and will also monitor the safety of the treatment. The trial is designed to be open-label, which means both the researchers and participants will know that Alectinib is being administered. The study will take place across multiple centers, allowing for a broader collection of data.

The trial will continue until the planned end date, with regular assessments to check the cancer’s response to the treatment. The main goal is to see if the cancer shows a significant reduction in viable tumor cells after treatment with Alectinib and before surgical removal. This study aims to provide valuable information on the potential benefits of using Alectinib as a pre-surgery treatment option for patients with ALK+ NSCLC.

Participants in the study will receive the treatments through an intravenous infusion, which means the medicine is given directly into a vein. The study will take place over a period of up to 12 months. During this time, doctors will monitor the patients to see how the cancer responds to the treatment and to check for any side effects. Some patients may receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatments.

The study aims to find out if the treatments can help achieve a complete response, meaning no cancer cells are found after surgery. It will also look at how long patients remain free of cancer after treatment and surgery. The results will help determine if these treatments can be a safe and effective option for people with early-stage .

The purpose is to evaluate if using a special imaging technique called FDG-PET to guide a faster-paced radiation treatment combined with chemotherapy and immunotherapy works as well as the standard treatment approach. During the study, patients will receive radiation therapy together with chemotherapy, followed by immunotherapy treatment with durvalumab, which will be given through an infusion into a vein.

The treatment period with durvalumab may continue for up to 12 months. Throughout the study, doctors will monitor patients’ response to treatment and check for any side effects. The study will also look at how long patients remain free from cancer progression and their overall survival, as well as measure their quality of life during and after treatment.

The purpose of the study is to evaluate the safety and effectiveness of combining Durvalumab with two different types of radiation therapy. One type is the conventional method, and the other is an optimized method called hypofractionated radiotherapy, which involves giving larger doses of radiation over a shorter period. The study aims to see how well these treatments work together in improving the response rates in patients with this type of lung cancer.

Participants in the study will receive either the conventional or the hypofractionated radiation therapy along with Durvalumab. The study will monitor the safety of these treatments and how well they are tolerated by the patients. It will also look at how the cancer responds to the treatment over time. The study is expected to last for a period of up to 12 months, during which patients will have regular hospital visits for treatment and follow-up examinations.

Participants in the study will receive treatments through an intravenous infusion, which means the medication is given directly into a vein. The medications used in the study include cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, which are all types of chemotherapy drugs. These drugs work by targeting and killing cancer cells. The study will also use durvalumab, an immunotherapy drug that helps the immune system recognize and attack cancer cells.

The study will take place over a period of time, with participants receiving treatment for up to 16 weeks. The goal is to determine if adding durvalumab after the initial treatment can help prevent the cancer from returning. Participants will be monitored throughout the study to assess their response to the treatment and any side effects they may experience. The study is designed to provide valuable information on improving treatment outcomes for patients with early-stage NSCLC.

The purpose of the study is to evaluate the effectiveness and safety of these treatments when given before and after surgery. The study will follow a course where patients receive the treatments before surgery to shrink the tumor, known as neoadjuvant treatment, and then continue with additional treatments after surgery, known as adjuvant treatment. The study aims to see how well these treatments work in reducing the cancer and how safe they are for patients.

Participants in the study will receive either the active medications or a placebo. The study will monitor the response of the cancer to the treatments, as well as any side effects experienced by the participants. The goal is to gather information that could help improve treatment options for patients with early-stage NSCLC that can be surgically removed.

The purpose of the study is to evaluate how effective atezolizumab is in preventing the cancer from getting worse over a period of 12 months. Patients participating in the trial will receive atezolizumab after completing their initial treatments of chemotherapy and radiotherapy. The study will monitor the patients’ health and the progression of their cancer over time to see if the medication helps in keeping the cancer from advancing.

Throughout the study, patients will be regularly assessed to check for any changes in their condition and to ensure their safety while taking atezolizumab. The trial aims to gather information on how well the medication works and any side effects it may cause. This information will help in understanding the potential benefits of atezolizumab for patients with this type of lung cancer.

The purpose of the study is to see how effective sotorasib is in reducing the size of tumors in patients with this type of lung cancer. Participants in the study will receive sotorasib and will be monitored over time to observe changes in their tumor size and overall health. The study will also look at how long patients can live without their disease getting worse and how long they respond to the treatment. Some patients may receive a placebo, which is a substance with no active medication, to compare the effects of sotorasib.

Throughout the study, various health assessments will be conducted to ensure the safety and well-being of the participants. These assessments will include monitoring for any side effects, changes in vital signs, and laboratory tests. The study aims to gather information on how sotorasib affects patients with different health conditions and how it interacts with other treatments they may have received. The trial is expected to continue until 2028, providing valuable insights into the treatment of KRAS G12C-mutated non-small cell lung cancer.

Participants in the study will be randomly assigned to one of two groups. One group will receive Ociperlimab in combination with Tislelizumab, while the other group will receive Pembrolizumab followed by a placebo. The treatments are given as infusions, which means they are administered directly into the bloodstream through a vein. The study will monitor the participants over a period of time to assess the effectiveness of the treatments in improving survival rates.

The trial aims to provide valuable information on how these treatments can help patients with non-small cell lung cancer. By comparing the different treatment options, researchers hope to find the most effective approach for managing this type of cancer. The study will also look at the quality of life of participants and any side effects they may experience during the trial.

Participants in the study will receive osimertinib as an initial treatment, known as induction therapy, before undergoing chemotherapy and radiation therapy. After these treatments, they will continue to take osimertinib as a maintenance therapy. The study will monitor the participants over a period of time to assess how well the treatment works and to check for any side effects. The study will also include a comparison with a placebo to evaluate the effectiveness of osimertinib.

The trial aims to gather information on how long patients live without their cancer getting worse, as well as other outcomes such as overall survival and response to treatment. The study will also look at the safety and tolerability of osimertinib by monitoring any adverse effects, changes in vital signs, and results from laboratory tests. This information will help determine if osimertinib is a beneficial treatment option for patients with unresectable NSCLC.

The purpose of the study is to evaluate whether adding radiotherapy to the standard chemotherapy and immune therapy can be effective and manageable for patients with this type of lung cancer. Participants in the study will receive these treatments before undergoing surgery to remove the cancer. The study will monitor how well the cancer responds to the treatments and how the treatments affect the patients’ health and recovery.

Throughout the study, patients will receive the treatments in a controlled manner, with careful monitoring by healthcare professionals. The study aims to gather information on the safety and effectiveness of this combined treatment approach, with the hope of improving the chances of successful surgery and long-term health for patients with advanced NSCLC.

The purpose of the study is to evaluate how well the combination of Tiragolumab and Atezolizumab works in preventing the return of cancer in patients whose tumors have a specific protein called PD-L1. The study will also look at the safety of these medications and how they affect the quality of life of the participants. Participants will receive the treatment over a period of up to 12 months, and their health will be monitored regularly to assess the effects of the treatment.

Throughout the study, researchers will collect information on how long participants remain free of cancer, any side effects they experience, and their overall survival. The study will also measure the levels of Tiragolumab and Atezolizumab in the blood at different times to understand how the body processes these medications. This trial aims to provide valuable insights into the potential benefits of combining Tiragolumab with Atezolizumab for treating NSCLC.

The main goal of the study is to assess the safety and how well patients tolerate ATL001 as a treatment. Participants in the study will receive the treatment through an infusion, which means the medication is given directly into the bloodstream. The study will monitor patients over time to see how their cancer responds to the treatment and to check for any side effects. The study will also compare the effects of the treatment with those of a placebo.

Throughout the study, patients will have regular check-ups to track their health and the progress of their cancer. The study will measure changes in tumor size and overall health outcomes, such as how long patients live without their cancer getting worse. This research aims to provide new insights into treating non-small cell lung cancer and potentially offer new options for patients with this type of cancer.

The purpose of the study is to see how effective Osimertinib is in keeping the cancer from progressing. Participants in the study will be randomly assigned to receive either Osimertinib or a placebo. The study is designed to be “double-blind,” which means neither the participants nor the researchers will know who is receiving the actual medication and who is receiving the placebo. This helps ensure that the results are not biased. The medication is taken orally in the form of film-coated tablets.

Throughout the study, participants will be monitored regularly to check on their health and to see how the cancer is responding to the treatment. This will involve various assessments, including physical exams and possibly imaging tests. The study aims to provide valuable information on whether Osimertinib can be an effective maintenance therapy for patients with this type of lung cancer, potentially improving their quality of life and extending the time before the cancer progresses.

The purpose of the study is to explore the possibility of performing surgery after patients have received high-dose chemotherapy and radiation therapy, which is a combination treatment often referred to as chemoradiotherapy. After surgery, the study will also look at whether patients can continue with Durvalumab as a follow-up treatment, known as consolidation therapy. This approach aims to see if adding surgery and Durvalumab can be a feasible treatment plan for patients with Stage III NSCLC.

Participants in the study will first undergo chemoradiotherapy. If surgery is deemed possible, it will be performed within 12 weeks after completing the chemoradiotherapy. Following surgery, patients will receive Durvalumab to help consolidate the treatment. The study will monitor the ability to perform surgery and the continuation of Durvalumab treatment, as well as any side effects or complications that may arise during the process.

The purpose of the study is to evaluate how effective Sotorasib is in treating this specific type of lung cancer. Participants will receive the medication and will be monitored over time to see how their cancer responds. The study will look at how long patients can live without their cancer getting worse, as well as other outcomes like overall survival and the safety of the treatment.

Throughout the study, participants will have regular check-ups and tests to monitor their health and the progress of their cancer. These tests may include imaging scans like PET-CT and MRI to ensure the cancer has not spread to other parts of the body. The study aims to provide valuable information on the potential benefits of Sotorasib for patients with this specific lung cancer mutation.

The purpose of the study is to determine how well osimertinib works in keeping the cancer from coming back, which is referred to as disease-free survival. Participants in the study will be randomly assigned to receive either osimertinib or a placebo. The study will be conducted in a way that neither the participants nor the researchers know who is receiving the actual medication or the placebo, a method known as double-blind. This helps ensure that the results are not influenced by expectations about the treatment.

Throughout the study, participants will be monitored for several years to assess the long-term effects of the treatment. This includes regular check-ups and tests to track their health and any changes in their condition. The study will also look at overall survival rates and the quality of life of the participants, using questionnaires and other assessments. The safety of the treatment will be closely watched by checking for any side effects or health changes during the study period.

Participants in the study will receive the treatments in a specific order, starting with THIO followed by Cemiplimab. Both medications are given through an intravenous infusion, which means they are administered directly into the bloodstream through a vein. The study will monitor participants over a period of time to observe any side effects and to see how well the cancer responds to the treatment.

The study aims to gather information on the safety of the treatment combination and its ability to control the cancer. Researchers will look at how the cancer responds to the treatment, including whether it shrinks or stops growing. The study will also track any side effects that occur and how severe they are. This information will help determine if the treatment is a viable option for people with advanced NSCLC.

The purpose of the study is to evaluate how well the combination of atezolizumab and tiragolumab works compared to durvalumab in patients with locally advanced, unresectable stage III NSCLC. “Unresectable” means that the cancer cannot be removed with surgery. The study will look at how long patients live without the cancer getting worse, which is known as progression-free survival. This will be assessed by an independent review facility, which is a group of experts who will review the results.

Participants in the study will receive their assigned treatment for up to 52 weeks. The study will monitor the patients’ health and the progression of their cancer during this time. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatments. The study aims to provide valuable information on the best treatment options for patients with this type of lung cancer.

Participants in the study will take INCB099280 in the form of a film-coated tablet. The study will test different doses of the medication, specifically 400 mg, 600 mg, and 800 mg, taken twice a day. The treatment period can last up to 24 weeks. During the study, participants will be monitored for any side effects and changes in their condition. Some participants may receive a placebo, which is a tablet that looks like the treatment but does not contain the active medication.

The study aims to gather information on how the treatment affects the tumors, including whether it can shrink them or stop them from growing. It will also look at how long any positive effects last and how the treatment impacts the overall health and survival of the participants. The results will help determine if INCB099280 could be a useful treatment option for people with these types of cancer in the future.

Participants in the study will be randomly assigned to one of the treatment groups. Some will receive brigatinib, which is taken orally as a film-coated tablet, while others may receive durvalumab or be under observation. The study will monitor the participants over a period to see how the cancer responds to these treatments. The main focus is on how long the cancer stays under control without progressing, which is known as progression-free survival. Other aspects like overall survival, which is the length of time patients live after starting the study, and the safety of the treatments will also be observed.

This trial is designed for patients with unresectable stage III NSCLC, meaning the cancer cannot be removed by surgery. It is important for participants to have completed their initial chemo-radiotherapy without the disease progressing. The study aims to provide valuable information on the effectiveness of brigatinib as a consolidation therapy, which is a treatment given after the initial therapy to strengthen its effect, in comparison to other options like durvalumab or observation.

Participants in the study will be randomly assigned to one of three groups. One group will receive nivolumab with chemoradiotherapy followed by nivolumab and ipilimumab. Another group will receive nivolumab with chemoradiotherapy followed by more nivolumab. The third group will receive chemoradiotherapy followed by durvalumab. The study will monitor how long patients live without the cancer progressing, as well as overall survival and response to the treatment.

The trial is designed to last several years, with regular check-ups and assessments to track the progress of the disease and the effects of the treatments. The study aims to provide valuable information on the best treatment options for patients with this type of lung cancer, potentially leading to improved outcomes and quality of life for those affected by the disease.